Tag: Ivig

According to the American Society of Hematology, corticosteroids are typically the first-line therapy for thrombocytopenia, particularly for immune thrombocytopenic purpura (ITP), an autoimmune disorder characterized by a low platelet count. The optimal approach, however, depends on the severity and underlying cause of the condition.

According to a 2018 survey by the Immune Deficiency Foundation, 98% of individuals using IVIG experienced side effects, with fatigue and dizziness among the most common. These reactions can significantly impact judgment and reaction times, which is why it is critical to understand the risks involved when asking, “Can you drive after an IVIG infusion?”

According to one study, some patients who receive Intravenous Immunoglobulin (IVIG) therapy report experiencing improvements in their energy levels as part of their overall treatment benefit. The question, **will IVIG give me energy**, has a complex answer that depends heavily on the root cause of your fatigue and how your body responds to the treatment.

Approximately 3,000 to 6,000 people in the US are diagnosed with Guillain-Barré syndrome (GBS) each year, a serious neurological condition sometimes referred to as the **Yan Beret syndrome** due to its phonetic spelling. This rare disorder is a medical emergency that requires prompt hospitalization and intensive care.

Approximately 12% of patients who develop hyperhemolysis syndrome (HHS) may face mortality, making prompt and effective intervention critical. This severe, post-transfusion complication requires a specialized approach, often beginning with immediate cessation of transfusions and initiating potent immunosuppressive therapies to address the uncontrolled red blood cell destruction.

While most commonly known as a pediatric illness, a rare form of Kawasaki disease can occur in adults, often leading to a delayed diagnosis due to its atypical presentation. Understanding **how is Kawasaki disease treated in adults** is crucial for preventing severe, long-term cardiovascular complications.

Unlike the inherited version, acquired von Willebrand syndrome (AVWS) is not genetic, often linked to an underlying medical condition like an autoimmune or lymphoproliferative disorder. Effectively managing this rare bleeding disorder involves a multi-pronged approach, focusing on controlling symptoms and addressing the root cause. How do you treat acquired von Willebrand syndrome and its associated bleeding risks?

According to research, the high cost and unselective nature of traditional plasma exchange have driven the development of more refined therapeutic options. Understanding what is the alternative to plasma exchange is vital for exploring modern treatment strategies that offer greater specificity and potentially fewer side effects.

According to the National Institutes of Health, immunoglobulin (IG) therapy is a standard treatment for individuals with antibody deficiencies and has been successfully used for over 40 years. So, **what is an IG used for** in a general health context? It refers to the medical use of immunoglobulin to bolster a compromised immune system and treat a wide range of diseases.

Every year, millions of liters of blood plasma are donated worldwide, with components used to create life-saving therapies for numerous conditions. The question, **what disease is treated by plasma**, has multiple answers, depending on the specific therapy derived from this critical blood component, highlighting its versatility in modern medicine.